Join our community of smart investors

Oxford/AstraZeneca trial paused due to illness

Standard review process has led the company to put studies on hold
Oxford/AstraZeneca trial paused due to illness

A late-stage trial for a potential Covid-19 vaccine being developed by Oxford University and AstraZeneca (AZN) has been paused, due to a possible serious adverse reaction in a participant. Health publication Stat News, which first reported the update on Tuesday evening, said that the participant in question was based in the UK and is expected to recover.

IC TIP: Buy at 8222p

To continue reading...
OR
Register for free
Read 3 articles for free each month
* Excl. premium articles
Have an account? Sign in